Cargando…

Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus

With the advent of antiretroviral therapy, lung cancer has become a crucial health problem among individuals living with human immunodeficiency virus (HIV). In East Asian populations, the frequency of lung cancer patients harboring epidermal growth factor receptor (EGFR) mutations is greater than in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuma, Yusuke, Hosomi, Yukio, Imamura, Akifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317148/ https://www.ncbi.nlm.nih.gov/pubmed/25678798 http://dx.doi.org/10.2147/OTT.S76712

Ejemplares similares

Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing “wax-and-wane” transformation
por: Takagi, Yusuke, et al.
Publicado: (2013)

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
por: Cortot, Alexis B., et al.
Publicado: (2014)

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
por: Nishio, Makoto, et al.
Publicado: (2019)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations
por: Yao, Shuyang, et al.
Publicado: (2016)

Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations
por: Chang, Ming-Hung, et al.
Publicado: (2022)

Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine
por: Akiyama, Norimichi, et al.
Publicado: (2017)

Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: ‘PRIDE’ Complex
por: Madke, Bhushan, et al.
Publicado: (2014)

Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report
por: SUN, QIONG, et al.
Publicado: (2014)

Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation
por: Ko, How-Wen, et al.
Publicado: (2022)

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib
por: Kanaoka, Kensuke, et al.
Publicado: (2023)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
por: Feng, Yongdong, et al.
Publicado: (2021)

Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M
por: Ogawara, Daiki, et al.
Publicado: (2017)

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
por: Okuma, Yusuke, et al.
Publicado: (2015)

Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
por: Masago, Katsuhiro, et al.
Publicado: (2015)

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
por: Kitadai, Rui, et al.
Publicado: (2022)

Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K‐ras mutation
por: Kaseda, Kaoru, et al.
Publicado: (2017)

The management of postoperative recurrence of non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation: what is the best way?
por: Adachi, Hiroyuki, et al.
Publicado: (2022)

Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor
por: Machado-Rugolo, J., et al.
Publicado: (2023)

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
por: Si, Jinfei, et al.
Publicado: (2023)

Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
por: Xu, Hongyu, et al.
Publicado: (2020)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Akazawa, Yuki, et al.
Publicado: (2023)

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report
por: WANG, YUE FENG, et al.
Publicado: (2014)

Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations
por: Zhang, Yan, et al.
Publicado: (2017)

Clinical outcome of thymic lymphoepithelioma-like carcinoma: Case report of a 14-year-old male
por: SEKIHARA, KUNIKO, et al.
Publicado: (2014)

Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review
por: Hashimoto, Kana, et al.
Publicado: (2016)

Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations
por: Miyauchi, Eisaku, et al.
Publicado: (2019)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)

FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
por: Odogwu, Lauretta, et al.
Publicado: (2017)

Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report
por: Zhai, Shu-Sen, et al.
Publicado: (2020)

Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
por: Zhang, Ling, et al.
Publicado: (2023)

Adenocarcinoma of the lung with positive epidermal growth factor receptor mutation in pregnancy
por: Amanda, Gina, et al.
Publicado: (2017)

METHYLATION STATUS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE IN LUNG CARCINOMA CELLS
por: Gamou, Shinobu, et al.
Publicado: (1988)

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study
por: Hosomi, Yukio, et al.
Publicado: (2022)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
por: Sato, Izumi, et al.
Publicado: (2020)

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
por: Tu, Chih-Yen, et al.
Publicado: (2018)

Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports
por: Liu, Yongmei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vjitgh73h36r2b9s0k4dv34nmg